GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

Glax­o­SmithK­line’s asth­ma drug Nu­cala, which re­ceived a re­sound­ing FDA re­jec­tion for use in chron­ic ob­struc­tive pul­monary dis­ease (COPD) last year, has shown promise in a rare blood dis­or­der.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER